Preferred Label : Elzovantinib;
NCIt synonyms : MET/Src/CSF1R Tyrosine Kinase Inhibitor TPX-0022; Multikinase Inhibitor TPX-0022; Multi-kinase Inhibitor TPX-0022;
NCIt definition : An orally bioavailable, multi-targeted kinase inhibitor with potential antineoplastic
activity. Upon oral administration, elzovantinib binds to and inhibits three tyrosine
kinases that are often overexpressed in a variety of cancer cell types, including
MET (c-Met; hepatocyte growth factor receptor; HGFR) , Src, and colony stimulating
factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; macrophage colony-stimulating factor
receptor; M-CSFR) thereby disrupting their respective signaling pathways. MET, a receptor
tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important
role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor
angiogenesis. Src, a non-receptor tyrosine kinase upregulated in many tumor cell types,
plays an important role in tumor cell proliferation, motility, invasiveness and survival.
CSF1R is a cell-surface receptor for colony stimulating factor 1 (CSF1); this receptor
tyrosine kinase is overexpressed by tumor-associated macrophages (TAMs) in the tumor
microenvironment (TME), and plays a major role in both immune suppression and the
induction of tumor cell proliferation.;
UNII : TTY12Q00LY;
CAS number : 2271119-26-5;
Molecule name : TPX 0022; TPX-0022;
NCI Metathesaurus CUI : CL973112;
Origin ID : C162676;
UMLS CUI : C5706654;
Semantic type(s)
- concept_is_in_subset
- has_target
